The mannose 6-phosphate/IGF-2 receptor has been proposed to be a tumor suppressor gene on the basis of loss of heterozygosity and mutations in tumors from cancer patients. To test this hypothesis, the receptor was expressed in 66cl4, a mouse mammary tumor cell line deficient in the receptor. Expression of the receptor corrected the abnormal lysosomal trafficking phenotype displayed by these cells. Receptor expression had no apparent effect on growth or invasiveness of the cells in vitro but effectively inhibited formation of mammary tumors in BALB/c mice. Analysis of cell proliferation and apoptosis in tumors indicated that the primary effect of the receptor was to inhibit cell proliferation. Proliferation indices for receptor-deficient and receptor-expressing tumors, as determined by BrdU incorporation, were 24.6 and 7.6%, respectively. No significant effect of receptor expression on apoptosis was observed. Receptor expression similarly inhibited tumor growth in BALB/c scid mice indicating that cytotoxic T cells and other components of the immune system missing in scid mice are not involved in the receptor's tumor suppressing effect. These findings establish a role for the receptor as a bona fide tumor suppressor gene and together with previous studies, suggest an important role for the receptor in human and rodent cancers.
Introduction
The Man-6-P/IGF-2 receptor is a multifunctional protein originally characterized with respect to its role in trafficking mannose phosphorylated hydrolases to lysosomes in mammalian cells and tissues (Sahagian et al., 1981) . Cloning and sequencing of the high-affinity receptor for IGF-2 led to the realization that the two receptors were the same protein (Morgan et al., 1987) that had distinct binding sites for the two ligands (Braulke et al., 1988; Kiess et al., 1988; MacDonald et al., 1988) . A number of studies have implicated the Man-6-P/IGF-2 receptor in IGF-2 signaling (Okamoto et al., 1990; Ikezu et al., 1995; McKinnon et al., 2001 ). However, a signaling role for the receptor has remained controversial and many investigators believe that the receptor's role in IGF-2 function is to moderate IGF-2 action by mediating its endocytosis and degradation (Filson et al., 1993; Lau et al., 1994; Wang et al., 1997) . Such a role is consistent with mouse knockout studies, which suggest that the receptor opposes the growthpromoting effects of IGF-2 and with proposals that the receptor acts as a tumor suppressor gene for several cancers (Filson et al., 1993; Lau et al., 1994; Wang et al., 1994 Wang et al., , 1997 .
More recently, a number of additional functions have been attributed to the receptor. The most extensively studied of these functions is plasmin-dependent activation of TGF-b, which is thought to occur while mannose phosphorylated TGF-b precursor is bound to the receptor at the cell surface (Dennis and Rifkin, 1991; Ghahary et al., 1999; Godar et al., 1999) . Man-6-P/IGF-2 receptor on the surface of tumor cells was shown to function as a death receptor for cytotoxic T-cell-induced apoptosis by mediating endocytosis of mannose phosphorylated granzyme B released by cytotoxic T cells (Motyka et al., 2000) . Evidence for additional binding sites on the receptor for urokinase-type plasminogen activator receptor (uPAR) (Nykjaer et al., 1998) , plasmin (Godar et al., 1999) and retinoic acid (Kang et al., 1997) has also been reported. Interaction of the receptor with uPAR appears to play a role in uPAR turnover (Nykjaer et al., 1998) . The functional basis for interaction of retinoic acid with the receptor is unclear although evidence has been reported suggesting a role for the receptor in retinoic acid-dependent growth inhibition (Kang et al., 1999) .
The Man-6-P/IGF-2 receptor has been proposed to be a tumor suppressor gene on the basis of loss of heterozygosity (LOH) and functional mutations in tumors. LOH at the Man-6-P/IGF-2 receptor locus was found to occur in 70% of hepatocellular carcinomas obtained from patients with primary liver cancer (Yamada et al., 1997) . In a substantial portion of these tumors, functional mutations were identified in the remaining allele. LOH and function mutations in tumors have since been reported for breast cancer (Hankins et al., 1996; Seitz et al., 2003) , head and neck cancer (Jamieson et al., 2003) , oral squamous cell carcinoma (Zavras et al., 2003) , lung cancer (Gemma et al., 2000; Kong et al., 2000; Oka et al., 2002) , adrenocortical cancer (Leboulleux et al., 2001) , and sporadic cancers of the gastrointestinal tract (Caligo et al., 2000; Calin et al., 2000) .
Further evidence that Man-6-P/IGF-2 receptor functions as a tumor suppressor has been obtained by reducing or augmenting receptor expression in tumor cells. Overexpression of the receptor in human colorectal carcinoma cells has been reported to decrease cell growth and increase apoptosis in culture (Souza et al., 1999) and similar experiments with the human JEG-3 choriocarcinoma cell line (O'Gorman et al., 2002) and the MDA-MB 231 (Lee et al., 2003) breast tumor cell line have demonstrated decreased growth both in vitro and in vivo. Reduced expression of the receptor produced by various antisense strategies has the opposite effect of increasing cell proliferation and, in some case, reducing apoptosis. Reduced expression was reported to increase growth of JEG-3 cells in vitro and in vivo (O'Gorman et al., 1999) and enhance IGF-IIinduced proliferation and reduce susceptibility to TNFinduced apoptosis in the MCF-7 cells (Chen et al., 2002) . While these studies provide information concerning possible roles of the receptor in the development of cancer, they have been carried out using cells with normal levels of the receptor that have acquired tumorigenic and metastatic characteristics through mechanisms other than those involving Man-6-P/IGF-2 expression. Consequently, phenotypic changes produced by altered expression of the receptor in these cells, may or may not reflect changes that occur naturally during tumor progression.
We recently reported the existence of naturally occurring cancer-associated deficiencies of the receptor in two mouse mammary tumor cell lines, 66cl4 and 168FARN (Tao et al., 2001) . The loss of receptor expression in these cells was presumed to be causatively related to the tumor-forming potential of these cells. In this study, a direct causative relationship between loss of receptor expression and tumorigenicity was demonstrated by showing that expression of the receptor in one of these lines, 66cl4, suppresses mammary tumor formation in vivo. In addition, the suppressive effect was shown to be caused by an inhibitory effect of the receptor on tumor cell proliferation rather than to previously reported roles in granzyme B-dependent killing by cytotoxic T cells and other apoptotic processes. The results establish a role for the Man-6-P/ IGF-2 receptor as a bona fide tumor suppressor gene and together with previous studies, suggest an important role for the receptor in a wide range of cancers in humans and rodents.
Results
The expression of Man-6-P/IGF-2 receptor in five cell lines derived previously from a single spontaneously arising mouse mammary tumor (Aslakson and Miller, 1992) is shown in Figure 1 . Normal steady-state levels of the receptor were observed in three of the lines, 67NR, 4T07 and 4T1. In contrast, two of the lines, 168FARN and 66cl4 displayed greatly reduced levels of receptor that were o15% of the normal 4T1 level. Biosynthetic labeling experiments and RT-PCR indicated that the low level of the receptor in the 66cl4 line was due to reduced synthesis resulting from a low receptor message level rather than to increased degradation of the receptor (data not shown).
The 66cl4 cell line is tumorigenic when implanted orthotopically in syngeneic BALB/c mice and metastasizes to lungs via the lymphatic system (Aslakson and Miller, 1992; Tao et al., 2001) . To demonstrate the ability of the Man-6-P/IGF-2 receptor to act as a tumor suppressor and to determine how it affects tumor growth and metastasis, Man-6-P/IGF-2 receptor was stably expressed in this line by transfection with the psFFVneo expression vector containing a full-length receptor cDNA under the control of the Friend splenic focus-forming virus LTR (Dole et al., 1994) . Four clones with receptor levels similar to the 4T1 cell line were isolated along with three control clones transfected Figure 1 Man-6-P/IGF-2 receptor levels in mouse mammary tumor cell lines. Cell lines were labeled for 24 h with [
35 S]methionine and Man-6-P/IGF-2 receptor was immunoprecipitated from cell extracts containing equivalent amounts of TCA-precipitable radioactivity and subject to SDS-PAGE and fluorography. The fluorogram was exposed for 5 days with empty psFFVneo vector (Figure 2 ). Receptor levels for the receptor expressing cell lines were in the range of 66-74% of the 4T1 level.
The receptor-expressing 66cl4 cell lines were characterized with respect to in vitro cell growth and invasiveness, and receptor function. As shown in Figure 3 , receptor-expressing lines 66cl4-m6PR-1, 66cl4-m6PR-4, 66cl4-m6PR-5 and 66cl4-m6PR-7 displayed in vitro doubling times of 23.4, 25.2, 24.8, and 23.1 h, respectively, similar to the doubling time of the parental 66cl4 line (24.5 h) and the two control cell lines, 66cl4-control-1 (23.3 h) and 66cl4-control-2 (24.8 h), that were examined. No significant difference in invasion through Matrigel was observed between receptorexpressing cell lines and the parental receptor-deficient line. Receptor-expressing cell lines, m6PR-1 and m6PR-4, displayed invasion indices of 2172.6 and 2571.8%, respectively, vs 2471.0% for the receptor-deficient line. To demonstrate functionality of the expressed receptor, lysosomal trafficking of endogenous cathepsin D and cathepsin L was examined in the receptor-expressing and receptor-deficient cell lines. Cells were cultured for 16 h and cathepsin levels in cell extracts and media were examined by Western blotting. The receptor-deficient lines displayed substantial secretion of procathepsin D into the culture medium (Figure 4 ), a condition expected for cells expressing subnormal levels of Man-6-P/IGF-2 receptor. A substantial amount of processed intermediate single chain cathepsin D was found in these cells suggesting that a significant portion of the enzyme is targeted to lysosomes. This targeting could be mediated by 46 kDa Man-6-P receptor, by residual Man-6-P/IGF-2 receptor, or by some other mechanism. The receptorexpressing cell lines displayed greatly reduced secretion of procathepsin D as expected for cells expressing normal levels of functional Man-6-P/IGF-2 receptor. Similar results were obtained for cathepsin L (data not shown).
Expression of Man-6-P/IGF-2 receptor was found to have a major effect on the ability of the 66cl4 cell line to form tumors in vivo. All four receptor-expressing lines showed substantially reduced tumor growth when injected into mammary fatpads of syngeneic BALB/c mice ( Figure 5 ). Average tumor mass 5 weeks after injection was 0.78 g (n ¼ 12, s.e.m. ¼ 0.040 g) for the parental and control cell lines, and 0.07 g (n ¼ 16, s.e.m. ¼ 0.015 g) for the receptor-expressing lines.
Tumors observed for the receptor-expressing lines varied from small tumors similar in hematoxylin-eosin (H&E) staining to those of the parental and control tumors, to small nodular masses composed primarily of connective tissue.
To examine the kinetics of tumor growth, a firefly luciferase gene was incorporated into selected cell lines (66cl4 and 66cl4-m6PR-1). The luciferase-expressing cells were injected into mammary fatpads of BALB/c mice and bioluminescence emitted from the animals after injection of luciferin, at various times after injection, was visualized and quantitated using a Xenogen biophotonic imager. Tumors of animals injected with the parental 66cl4 cell line grew rapidly with luminescence increasing exponentially between 4 and 18 days after injection ( Figure 6 ). An average doubling time of 46.1 h was calculated from log plots for the two animals injected with this line (Figure 6 insert). In contrast, luminescence of tumors produced in animals injected with the receptor-expressing line remained relatively constant for a few days and decreased thereafter. These results indicate that receptor expression produces a major alteration in the in vivo growth characteristics of the 66cl4 cell line. The alteration could involve decreased cell proliferation, increased cell death, or both.
Proliferation and cell death were examined in tumors produced by receptor-deficient and receptor-expressing cell lines ( Figure 7 , Table 1 ). Bromodeoxyuridine (BrdU) incorporation was used to assess proliferation; DNA laddering and cleaved caspase-3 staining was used to assess cell death. Tumors obtained from animals 5 weeks after injection that were >0.05 g in size were used for analysis. Tumors produced by receptor-expressing lines that had reached this size were similar in composition by H&E staining (Figure 7a and b) to the larger tumors produced by the receptor-deficient lines. Proliferation indices calculated from BrdU-stained Figure 2 Man-6-P/IGF-2 receptor levels in receptor-deficient and receptor-expressing cell lines. Man-6-P/IGF-2 receptor levels in receptor-deficient and receptor-expressing 66cl4 cell lines were determined by SDS-PAGE and Western blotting with antireceptor antibody as described in Materials and methods (Table 1 ). The average proliferation index for the receptor-deficient lines was 24.6 vs 7.6% for the receptor-expressing lines, a difference of 3.2-fold. A difference in growth rate of this magnitude is sufficient to account for the differences in tumor mass observed for receptor-deficient and receptor-expressing cell lines ( Figure 5 ). Tumors produced by both receptor-deficient and receptor-expressing lines displayed a similar level of cell death, as assessed by DNA laddering (Figure 8 ). DNA laddering is a measure of cell death produced by either apoptosis or necrosis (Arends et al., 1990; Hale et al., 1996) . Apoptosis was measured independently by cleaved caspase-3 immunohistochemistry (Figure 9 ). Quantitation of the results is given in Table 2 . Two forms of Figure 6 Luciferase imaging of tumor growth. Luciferase-containing cell lines 66cl4-luc and 66cl4-m6PR-1-luc were injected into the mammary fatpads of two mice for each cell line. At the indicated times, the animals were imaged using a Xenogen IVIS 100 imager as described in Materials and methods. Animals A and B were injected with 66cl4-luc and animals C and D were injected with 66cl4-m6PR-1-luc. Fold increases in luciferase light emission relative to the zero time values were plotted. Animal A (J), animal B ('), animal C (m), animal D (E). The inset shows the log plot of the data that was used to calculate tumor doubling times for animals A and B
Tumor suppression by Man-6-P/IGF-2 receptor J Li and GG Sahagian apoptosis were observed. Large regions of apoptosis, in which the majority of cells were apoptotic, were observed in some but not all tumors (Figure 9a-d) . These regions were larger and represented a greater portion of receptor-deficient tumors than of tumors derived from receptor-expressing lines (1.7670.38 vs 0.1170.06%). This apoptosis is presumably caused by reduced oxygenation and nutrient supply in poorly vascularized regions of the tumors. Such regions are expected to be more extensive in the larger, more rapidly growing receptor-deficient tumors. Scattered apoptotic cells were observed in all tumors (Figure 9a , b and e, f). No significant difference in the numbers of these cells was observed in receptor-deficient and receptor-expressing tumors (Table 3) . Taken together, the results indicate that the primary effect of receptor expression is to reduce the in vivo cell proliferation rate of the 66cl4 cell line. Cell death did occur in tumors produced by both receptor-deficient and receptor-expressing cell lines but no evidence for a stimulatory effect of the receptor on apoptosis was observed. The variability of tumor growth (i.e., slow growth vs regression) observed for different receptorexpressing lines in different animals as seen in Figures 5 and 6 most likely reflects minor differences in rates of proliferation and apoptosis that shift the balance in favor of slow tumor growth or regression. Tumor suppression by Man-6-P/IGF-2 receptor J Li and GG Sahagian
To investigate possible immune system involvement in tumor suppression by the Man-6-P/IGF-2 receptor, growth of receptor-deficient and receptor-expressing cell lines was examined in BALB/c SCID mice. Growth of tumors produced by fatpad injection of receptordeficient and receptor-expressing lines (Table 4) was similar to that observed for normal BALB/c mice ( Figure 5 ) indicating that T cell, B cell, and other immune system components missing in SCID mice are not required for suppression of tumor growth by the receptor.
Discussion
The results of this study provide direct evidence that the Man-6-P/IGF-2 receptor is a tumor suppressor gene for 
Apoptosis was calculated as the percentage of area of DAB staining for cleaved caspase-3 vs the total area of the tumor. n represents the number of sections. Each value is expressed as percentage of apoptosis area7s.e. The comparison for 66cl4 vs 66cl4-m6PR cell lines using the Student's t-test was Po0.01 Tumor suppression by Man-6-P/IGF-2 receptor J Li and GG Sahagian breast cancer in mice. Suppression of tumor growth was demonstrated using an orthotopic model in syngeneic mice by re-expression of the receptor in a tumor cell line that lost receptor expression naturally during the process of tumor progression. The primary effect of receptor re-expression was to reduce the rate of proliferation of the cells in vivo; proliferation of the cells in vitro was unaffected. Manifestation of the inhibitory effect of the receptor on cell proliferation in vivo but not in vitro presumably reflects differences in in vivo and in vitro growth condition. One possibility is that, in vivo, lysosomal hydrolases secreted by receptordeficient tumor cells cause release of factors from extracellular matrix that stimulate tumor growth. Further study will be required to determine the basis for the effects of the receptor on tumor cell proliferation in vivo. Previous studies supporting a tumor suppressor role for the Man-6-P/IGF-2 receptor have involved augmentation or reduction of receptor levels in cells that normally express the receptor. Using such approaches, effects on in vitro and in vivo growth have been observed. In contrast to this study, altered receptor expression produced changes in proliferation, apoptosis and/or invasiveness of the cells in vitro. Whether such variations reflect differences in cell origin, culture conditions, or other factors is unclear. The similarity of in vitro growth characteristics for the various receptor-deficient and receptor-expressing clones obtained for this study, however, ensures that differences in in vivo growth characteristics did not result from a bias in selecting clones for analysis. The substantial difference in proliferation index for receptor-deficient and receptorexpressing tumors observed in this study suggests that the primary effect of receptor expression is on cell proliferation. Significant receptor-dependent differences in apoptosis were not observed.
Of the five sibling cell lines examined, two, 66cl4 and 168FARN were found to be deficient in Man-6-P/IGF-2 receptor. From the results of this study it is clear that loss of receptor expression in the 66cl4 line is required for tumorigenesis. Presumably, reduced expression of the receptor in the 168FARN line is also required for tumorigenesis. In contrast, the remaining three cell lines are as tumorigenic as the receptor-deficient lines despite normal levels of the receptor (Aslakson and Miller, 1992) . The dependence of tumorigenicity on receptor loss in some lines but not others suggests that different alterations in gene expression are responsible for the tumorigenicity of the lines, even though the lines were originally derived from the same tumor. Loss of receptor expression may be more compatible with certain pathways of tumor progression than others and may alter the spectrum of productive cancer-producing pathways once it occurs. In this regard it will be of interest to see if analysis of receptor levels will have prognostic value for breast cancer in humans.
If the suppressive effect of the receptor on tumor growth is to be exploited for therapeutic use, the nature of the suppression needs to be explored further. While initially characterized with respect to its role in lysosomal enzyme trafficking (Sahagian et al., 1981) and IGF-2 endocytosis (Tong et al., 1988) , the receptor has been reported to be involved in a number of other growth-related processes including TGF-b activation (Dennis and Rifkin, 1991) , growth suppression by retinoic acid (Kang et al., 1999) , granzyme B-mediated cytotoxicity (Motyka et al., 2000) , and uPA receptor turnover (Nykjaer et al., 1998) . With the exception of granzyme B-mediated cytotoxicity, which is ruled out by the SCID mouse experiment described here, any or all of these functions could potentially be involved in tumor suppression. In fact, it may be the multiplicity of growth-related functions that makes the receptor an attractive target for tumor cells to exploit for progression to more aggressive phenotypes. It is also possible that different cancers, different tumors, or even different cells within the same tumor exploit the spectrum of receptor functions differently. The two naturally occurring receptor-deficient cell lines described in this study (i.e., 66cl4 and 168FARN) will provide a means of assessing the functional basis for tumor suppression by the Man-6-P/IGF-2 receptor.
Materials and methods

Materials
The 67NR, 168FARN, 66cl4, 4TO7 and 4T1 mouse mammary tumor cell lines were obtained from Dr Fred Miller at Wayne State University. Matrigel was purchased from BD Bioscience. The psFFVneo vector containing bovine Man-6-P/IGF-2 receptor (Lobel et al., 1987 ) (psFFVneo-m6PR) was provided by Dr Peter Lobel at Robert Wood Johnson School of Medicine. The luciferase-containing pGL3 Control vector was obtained from Stratagene. Dulbecco's modified Eagle's medium (DMEM), Dulbecco's phosphate-buffered saline without calcium and magnesium (PBS), fetal bovine serum (FBS), newborn calf serum (NCS), nonessential amino acids (NEAA), lipofectamine PLUS reagent and neomycin were from Invitrogen. CellTrackert Orange was from Molecular Probes. ChemoTx plates were purchased from Neuro Probe Inc. ApoAlert-PCR kit was from Clontech. DNeasy kit was from Qiagen. Puromycin, anti-rabbit-IgG-HRP, bromodeoxyuridine (BrdU), and proteinase inhibitor cocktail were from Sigma. Sheep anti-BrdU antibody was purchased from Maine Biotechnology Service. DAPI-containing mounting medium was from Vector Laboratories. An IgG fraction containing antibody directed against human caspase-3 cleaved at Asp175 was purchased from Cell Signaling. Affinity-purified ) were injected into fatpad 4 of female BALB/ SCID mice. After 5 weeks, the tumors were dissected and weighted. n represent the number of mice. Data shown are the mean7s.e. for each cell line. The comparison of 66cl4 vs 66cl4-m6PR cell lines using the Student's t-test was Po0.01
Tumor suppression by Man-6-P/IGF-2 receptor J Li and GG Sahagian Rhodamine Redt-X-conjugated donkey anti-sheep IgG was from Jackson ImmunoResearch. VECTORSTAIN Elite ABC kit (Rabbit IgG), DAB substrate kit for peroxidase and Hematoxylin QS were purchased from Vector Laboratories. Rabbit anti-human cathepsin D serum (Cuozzo et al., 1998) , affinity-purified rabbit anti-mouse cathepsin L antibodies (Cuozzo et al., 1995) , and affinity-purified rabbit anti-bovine Man-6-P/IGF-2 receptor antibodies (Tao et al., 2001 ) were prepared as previously described.
Cell culture
Cell lines were cultured in high glucose DMEM supplemented 5% FBS, 5% NCS, NEAA and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) at 371C in a humidified atmosphere containing 5% CO 2 . To minimize genetic drift, all analyses were performed on same passage cells within 3 weeks after thawing.
Labeling of cells and immunoprecipitation of Man-6-P/IGF-2 receptor
Prior to labeling, confluent cells were trypsinized and seeded at 10% confluency in 10 cm dishes and cultured for 3 days to yield a density of 70-90% confluency. Cells were then labeled for 24 h in 4 ml of DMEM containing 10% dialysed FCS, 100 mCi/ml [ 35 S]methionine, and 3% of the normal amount of unlabeled methionine. The receptor was immunoprecipitated from detergent extracts of the cells and subjected to SDS-PAGE and fluorography, as previously described (Tao et al., 2001) .
Transfection of cells and isolation of cell lines
Receptor-deficient and receptor-expressing cell lines were obtained by transfecting the 66cl4 cell line with psFFVneo or psFFVneo-m6PR in six-well culture plates using lipofectamine PLUS reagent as described by the vendor (Invitrogen). After 24 h, cells were trypsinized and replated in 10 cm culture dishes. After 48 h, G418 (500 mg/ml) was added as a selective agent. Fresh selective medium was added every 3 days until visible colonies were apparent. Single colonies were picked and expanded in selective medium and assayed for Man-6-P/IGF-2 receptor expression by Western blotting.
For obtaining luciferase-containing cells for biophotonic imaging, 66cl4 and 66cl4-m6PR-1 cell lines were cotransfected with luciferase-containing pGL-3 vector and the puromycincontaining vector, pKO-puro. Transfected cells were selected with puromycin and cloned. Lines displaying the highest level of luciferase expression were used for imaging.
Matrigel invasion assay
A modification of the high throughput method developed by Jay and coworkers (Beck et al., 2002) was used. Filters at the bottom of each well of a 96-well, 8 mm pore size CHEMOTx plate were coated with Matrigel (4 mg). Just prior to analysis, 60-80% confluent cells in 10-cm culture dishes were rinsed with DMEM and incubated in DMEM containing 3 mM CellTrackert Orange for 15 min at 371C. The cells were trypsinized and counted and 4 Â 10 4 cells in 60 ml of DMEM were loaded on each filter. FBS (5%) and NCS (5%) were added to DMEM in the lower chamber as the chemoattractant. The whole system was incubated for 20 h at 371C. The upper side of the filter was scrapped to remove uninvading cells. Fluorescence remaining on the lower side of the filter was read on a Tecan Spectrafluor Plus plate reader. Each sample was done in triplicate. Invasion was expressed as invasion index calculated by determining the percentage of total cells applied to the upper surface of the filter that were detected on the lower side of the filter.
Analysis of cathepsin trafficking
Cells were seeded into six-well culture plates at a density of 5 Â 10 5 /well. At 50% confluency, cells were washed with PBS and incubated at 371C for 16 h in 1 ml serum-free DMEM. Media were removed and cells were extracted with RIPA buffer (10 mM Tris-HCl, pH 8.0, 0.14 M NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) containing proteinase inhibitors. Aliquots of cell extracts and media, corrected for cell protein, were subjected to SDS-PAGE and Western blotting. Western blotting was done with rabbit antihuman cathepsin D serum (1 : 5000 dilution) or affinitypurified anti-mouse cathepsin L antibody (1 : 10 000 dilution) as primary antibody and anti-rabbit IgG-HRP (1 : 5000 dilution) as secondary antibody. Bands were detected by chemiluminescence.
Cell growth in vitro
Cells were seeded in triplicate into six-well culture plates at a density of 2 Â 10 4 /well and cultured in DMEM containing 5% FBS, 5% NCS, NEAA and antibiotics. At days 1, 2, 3, 4, and 5, cells were trypsinized and counted with a hemocytometer.
Tumor growth in vivo
Receptor-deficient and receptor-expressing cell lines were plated at 40% confluency and cultured for 24 h. The cells were then trypsinized, washed, and resuspended in DMEM containing NEAA at 2 Â 10 7 /ml and kept on ice before injection. Aliquots (100 ml) of the cells were injected into the No. 4 fatpad of 4-6-week-old female BALB/c or BALB/scid mice using a 27-gauge needle. Only cell preparations with viability >97%, as determined by Trypan blue exclusion, were used for injection. At 5 weeks after injection, primary tumors were removed from the animals and weighed.
Biophotonic imaging of tumors in mice
Luciferase-containing 66cl4 and 66cl4-m6PR-1 cells were injected into the No. 4 fatpad of BALB/c mice as described above. At various times after injection of the cells, mice were anesthetized with ketamine (100 mg/kg) and xylazine (7 mg/ kg). D-luciferin (1 mg) was injected intraperitoneally and after 5 min, light emitted from primary tumors were imaged and quantitated using a Xenogen IVIS 100 imager.
Analysis of in vivo proliferation
BrdU (50 mg/kg) was injected subcutaneously into the dorsal neck region of tumor-bearing mice and the mice were killed after 2 h. Tumors were dissected on ice, embedded in OCT solution and frozen at À801C for cryosectioning. Cryosections on glass slides were fixed for 15 min with 2% paraformaldehyde containing 0.1% Triton X-100 in PBS. After washing with PBS, the slides were incubated with 0.5 N HCl for 10 min to expose the BrdU incorporated into DNA. The slides were then neutralized with 0.1 M sodium borate, pH 8.5, by incubation for 10 min. After washing with PBS, the slides were incubated with sheep anti-BrdU antibody at 1 : 100 dilution in PBS for 1 h. After washing again with PBS, the slides were incubated with affinity-purified Rhodamine Red-Xconjugated donkey anti-sheep IgG at a 1 : 100 dilution in PBS for 1 h. After another wash, DAPI-containing mounting medium and coverslips were added. The slides were examined with a Zeiss Axiovert 10 microscope and pictures were taken with a Hamamatsu Digital camera. Sections at a depth of approximately 25, 50, and 75% were examined for each tumor. Two to four randomly chosen fields were examined in each section. The number of BrdU-stained cells as a percentage of total DAPI-stained cells was determined.
DNA laddering assay
The ApoAlert-PCR kit from Clontech was used for analysis of DNA laddering in receptor-deficient and receptor-expressing tumors. This assay is based on the TUNEL assay (Gavrieli et al., 1992) , a method widely used for detecting DNA nicks in apoptotic cells. For the analysis, genomic DNA was purified from fresh tumor samples using Qiagen's DNeasy kit. Adaptors were ligated to the ends of DNA fragments in the samples and the fragments were amplified by PCR and visualized by ethidium bromide staining after agarose gel electrophoresis using methods described by the vendor(Clontech).
Cleaved caspase-3 immunohistochemistry
Paraffin sections were used for cleaved caspase-3 immunohistochemistry. For each tumor, sections were obtained from three regions corresponding to depths of approximately 25, 50 and 75%. After deparaffinization and hydration, the sections were heated in a microwave oven for 10 min in 10 mM sodium citrate buffer (pH 6.0) to unmask antigens (Cattoretti et al., 1993) . The slides were then sequentially washed with PBS and incubated with 1% hydrogen peroxide for 10 min, blocking solution (PBS containing 1.5% goat serum) for 1 h at RT, cleaved caspase-3 antibody (1 : 200 in PBS) for 16 h at 41C, and biotinylated anti-rabbit IgG (1 : 200 dilution in PBS) for 30 min at RT. Immune complexes were then stained with streptavidin-HRP complexes and DAB using the VECTRORSTAIN Elite ABC Kit, as described by the vendor (Vector Laboratories). Sections were counterstained with hematoxylin.
For quantitation of apoptosis in receptor-deficient and receptor-expressing tumors, sections of tumors were photographed at Â 4 and Â 400 magnification using a Olympus Vanox-T microscope and Olympus U-PMTVC CCD camera. Large regions of apoptosis, in which most cells stained positive for cleaved caspase-3, were quantitated from Â 4 magnification fields by determining the percentage of the total tissue area that these regions represent. Six sections from two tumors for receptor-deficient cell lines, and 12 sections from four tumors for receptor-expressing cell lines were used for the analysis. Scattered apoptosis in areas of tumor tissue outside of the large regions of apoptosis was quantitated from Â 400 magnification fields by determining the percentage of total cells staining positive for cleaved caspase-3. Five to seven randomly chosen fields in each section, excluding those containing large regions of apoptosis, were examined for each tumor.
